Prelude Therapeutics Debt to Equity

The latest debt-to-equity ratio for PRLD is 0.32. That is above the Healthcare sector average of 0.3. Investors often review this figure alongside Prelude Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, PRLD currently prints 0.32 for debt-to-equity ratio, while the sector average sits near 0.3. That is roughly 6.6% above the sector mean. Large gaps often invite a closer look at Prelude Therapeutics's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.32 for Prelude Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (0.3) and with PRLD's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting PRLD's debt-to-equity ratio (0.32), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Prelude Therapeutics's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.